May 27, 2018 12:54 PM ET


Company Overview of Ranbaxy Laboratories Ltd.

Company Overview

Ranbaxy Laboratories Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical products. The company offers generics, differentiated products, over-the-counter products, anti-retrovirals, active pharmaceutical ingredients, and intermediates. Its products are used for the treatment in various therapy areas, including anti-infectives, cardiovascular, pain and musculoskeletal, central nervous system, gastrointestinal, respiratory, anti-retrovirals, dermatology, orthopaedics, nutritionals, urology, and diabetes. The company offers a portfolio of approximately 500 molecules in the forms of tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Ranbax...

Devika Tower

12th Floor

6, Nehru Place

New Delhi,  110019


Founded in 1961

15,300 Employees


91 11 2623 7508


91 11 2622 5987

Key Executives for Ranbaxy Laboratories Ltd.

Chief Executive Officer, Managing Director and Executive Director
Age: 62
President, Global Head of Technical Operations, Supply Chain, Procurement & API Marketing
President and Chief Financial Officer
Age: 61
President and Head of Global Research & Development
Chief Executive Officer of Indian Operations
Age: 60
Compensation as of Fiscal Year 2017.

Ranbaxy Laboratories Ltd. Key Developments

A United States Appeals Court Revives an Antitrust Lawsuit against Ranbaxy, Pfizer, Wyeth and Teva

A United States appeals court has revived an antitrust lawsuit against four drug makers, alleging that they hamstrung generics for Lipitor and Effexor XR. The plaintiffs, a coalition of labor unions and retailers, including Rite Aid and Walgreens, accused four drug makers of reverse settlement payment deals, in which a drug’s patent holder pays the accused infringer not to produce the patented item. The plaintiffs allege Ranbaxy accepted such payments from Pfizer to delay generics for Lipitor, while Wyeth accepted payments from Teva to delay Effexor XR. A federal judge earlier dismissed the claims, but this week the U.S. Court of Appeals for the Third Circuit in Philadelphia reversed the ruling.

Ranbaxy Opens its First Production Facility in Egypt

Sun Pharma (India) has announced that its subsidiary Ranbaxy (India) has opened its first production facility in Egypt. The factory will focus on generics manufacturing and will start by producing four different drugs for cardiovascular diseases this year, with a production capacity of 50 million capsules per year, according to Hany Mashaal, country general manager at Sun Pharma and regional manager at Ranbaxy. The new plant will be the first for Ranbaxy in Egypt and the Middle East region, said Mashaal, quoted by the Al-Ahram news agency.

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ranbaxy Laboratories Ltd., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at